Jeremy Grantham Eli Lilly & CO Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

$27.2 Billion
Q1 2024

A detailed history of Jeremy Grantham (Grantham, Mayo, Van Otterloo & Co. LLC) transactions in Eli Lilly & CO stock. As of the latest transaction made, Grantham, Mayo, Van Otterloo & Co. LLC holds 683,786 shares of LLY stock, worth $527 Million. This represents 1.95% of its overall portfolio holdings.

Number of Shares

683,786

Previous 689,863 0.88%

Holding current value

$527 Million

Previous $402 Million 32.28%

% of portfolio

1.95%

Previous 1.79%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$592.2 - $792.28 $3.6 Million - $4.81 Million	-6,077 Reduced 0.88%	683,786 $532 Million
Q4 2023 Feb 13, 2024	BUY	$525.19 - $619.13 $16 Million - $18.8 Million	30,370 Added 4.61%	689,863 $402 Million
Q3 2023 Nov 13, 2023	SELL	$434.7 - $599.3 $68.2 Million - $94 Million	-156,780 Reduced 19.21%	659,493 $354 Million
Q2 2023 Aug 14, 2023	BUY	$350.74 - $468.98 $9.97 Million - $13.3 Million	28,426 Added 3.61%	816,273 $383 Million
Q1 2023 May 12, 2023	BUY	$310.63 - $364.82 $3.38 Million - $3.97 Million	10,877 Added 1.4%	787,847 $271 Million

Q4 2022 Feb 13, 2023	SELL	$321.55 - $374.67 $3.17 Million - $3.7 Million	-9,871 Reduced 1.25%	776,970 $284 Million
Q3 2022 Nov 10, 2022	SELL	$296.48 - $337.87 $909,600 - $1.04 Million	-3,068 Reduced 0.39%	786,841 $254 Million
Q2 2022 Aug 12, 2022	SELL	$278.73 - $327.27 $38 Million - $44.6 Million	-136,417 Reduced 14.73%	789,909 $256 Million
Q1 2022 May 13, 2022	SELL	$234.69 - $291.66 $15.1 Million - $18.8 Million	-64,469 Reduced 6.51%	926,326 $265 Million
Q4 2021 Feb 11, 2022	SELL	$224.85 - $279.04 $3 Million - $3.72 Million	-13,334 Reduced 1.33%	990,795 $274 Million
Q3 2021 Nov 12, 2021	BUY	$221.6 - $272.71 $3.26 Million - $4.01 Million	14,707 Added 1.49%	1,004,129 $232 Million
Q2 2021 Aug 12, 2021	SELL	$180.55 - $233.54 $33.6 Million - $43.5 Million	-186,299 Reduced 15.85%	989,422 $227 Million
Q1 2021 May 13, 2021	BUY	$164.32 - $212.72 $3.85 Million - $4.98 Million	23,403 Added 2.03%	1,175,721 $220 Million
Q4 2020 Feb 12, 2021	SELL	$130.46 - $172.63 $27.1 Million - $35.8 Million	-207,505 Reduced 15.26%	1,152,318 $195 Million
Q3 2020 Nov 13, 2020	BUY	$146.22 - $169.13 $4.73 Million - $5.48 Million	32,382 Added 2.44%	1,359,823 $201 Million
Q2 2020 Aug 13, 2020	SELL	$136.42 - $164.18 $674,869 - $812,198	-4,947 Reduced 0.37%	1,327,441 $218 Million
Q1 2020 May 14, 2020	SELL	$119.05 - $147.35 $53.6 Million - $66.4 Million	-450,536 Reduced 25.27%	1,332,388 $185 Million
Q4 2019 Feb 13, 2020	BUY	$106.92 - $132.43 $214,267 - $265,389	2,004 Added 0.11%	1,782,924 $234 Million
Q3 2019 Nov 13, 2019	BUY	$106.79 - $116.16 $20.2 Million - $22 Million	189,524 Added 11.91%	1,780,920 $199 Million
Q2 2019 Aug 13, 2019	BUY	$110.79 - $129.32 $173 Million - $202 Million	1,563,537 Added 5612.32%	1,591,396 $176 Million
Q1 2019 May 14, 2019	SELL	$111.31 - $131.02 $31.4 Million - $37 Million	-282,200 Reduced 91.01%	27,859 $3.62 Million
Q4 2018 Feb 13, 2019	SELL	$105.9 - $118.64 $6.71 Million - $7.52 Million	-63,400 Reduced 16.98%	310,059 $35.9 Million
Q3 2018 Nov 14, 2018	SELL	$85.86 - $107.31 $4.3 Million - $5.38 Million	-50,100 Reduced 11.83%	373,459 $40.1 Million
Q2 2018 Aug 14, 2018	SELL	$75.7 - $86.88 $68.6 Million - $78.7 Million	-905,790 Reduced 68.14%	423,559 $36.1 Million
Q1 2018 May 15, 2018	BUY	$74.21 - $87.6 $25.9 Million - $30.5 Million	348,500 Added 35.53%	1,329,349 $103 Million
Q4 2017 Feb 14, 2018	BUY	$81.94 - $87.89 $14.7 Million - $15.7 Million	178,800 Added 22.29%	980,849 $82.8 Million
Q3 2017 Nov 14, 2017	SELL	$77.07 - $85.54 $5.03 Million - $5.58 Million	-65,224 Reduced 7.52%	802,049 $68.6 Million
Q2 2017 Aug 14, 2017	BUY	N/A	867,273	867,273 $71.4 Million

Others Institutions Holding LLY

# of Institutions

3,703

Shares Held

738M

Call Options Held

7.09M

Put Options Held

7.24M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $732B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track Jeremy Grantham's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.

Account